Jiksak Bioengineering
Jiksak Bioengineering aims to create a world where intractable neurological diseases can be cured using proprietary human nerve technology, focusing on drug discovery, nerve allograft, and regenerative medicine. The company develops innovative therapies and devices such as nerve conduits and drug delivery systems to address nerve injuries and neurodegenerative diseases.
Industries
Nr. of Employees
small (1-50)
Jiksak Bioengineering
CYBERNICS MEDICAL INNOVATION BASE-A room 322, 3-25-16 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821, Japan
Products
Microfluidic culture chip (PDMS–glass)
PDMS–glass microfluidic culture chip intended for neural tissue/organoid culture; documentation and user manual available.
Microfluidic culture chip (COP material)
Microfluidic culture chip manufactured in COP material for neural tissue culture; documentation and user manual available.
B-chip microfluidic device
Additional microfluidic device offering for neural culture workflows; user manual available.
Axon-integrated artificial nerve conduits (preclinical)
Implantable biodegradable conduit products incorporating acellular axon-bundle scaffolds intended to support peripheral nerve regeneration in preclinical development.
Microfluidic culture chip (PDMS–glass)
PDMS–glass microfluidic culture chip intended for neural tissue/organoid culture; documentation and user manual available.
Microfluidic culture chip (COP material)
Microfluidic culture chip manufactured in COP material for neural tissue culture; documentation and user manual available.
B-chip microfluidic device
Additional microfluidic device offering for neural culture workflows; user manual available.
Axon-integrated artificial nerve conduits (preclinical)
Implantable biodegradable conduit products incorporating acellular axon-bundle scaffolds intended to support peripheral nerve regeneration in preclinical development.
Services
Target identification and compound screening using human iPS cell–derived nerve organoids and chip-based assays.
Joint development agreements to scale and commercialize iPS cell–derived nerve tissue and device integrations with industrial partners.
Target identification and compound screening using human iPS cell–derived nerve organoids and chip-based assays.
Joint development agreements to scale and commercialize iPS cell–derived nerve tissue and device integrations with industrial partners.
Expertise Areas
- Neural tissue engineering
- Organoid-based preclinical models
- Targeted delivery to neuromuscular junctions
- Microfluidic culture systems
Key Technologies
- 3D nerve organoids
- Microfluidic culture chips (PDMS–glass, COP)
- Decellularized axon scaffolds
- Targeted delivery carriers for NMJ
News & Updates
Jiksak Bioengineering secured 800 million yen in Series B funding to support its growth and development.
A collaboration to develop and commercialize nerve tissue generated from human iPS cells.
Research using Nerve Organoids™ to identify genes involved in ALS.
A joint development project for a nerve organoid device with electrode chip integration.
Partnership to advance ALS drug discovery and regenerative medicine.
A recent publication detailing advancements in DLC technology.
Jiksak Bioengineering secured 800 million yen in Series B funding to support its growth and development.
A collaboration to develop and commercialize nerve tissue generated from human iPS cells.
Research using Nerve Organoids™ to identify genes involved in ALS.
A joint development project for a nerve organoid device with electrode chip integration.
Partnership to advance ALS drug discovery and regenerative medicine.
A recent publication detailing advancements in DLC technology.